Zimbabwe has rejected a substantial American health deal worth $367m (272 million pounds) spanning five years due to the United States' demand for sensitive biological samples.
This rejection was revealed following a official document from December was disclosed, indicating that President Emmerson Mnangagwa felt the arrangement was "skewed".
An official spokesperson has since explained that the United States was requesting biological samples for research and profit but was not willing to guarantee the benefits from any future vaccines.
"We will now turn to the challenging and unfortunate task of scaling back our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had provided over $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for more talks to secure a agreement acceptable to all parties so the nation's critical HIV programme can be sustained.
Wider Background
Zimbabwe's decision follows a comparable case in Kenya, where a court halted a related health funding agreement after concerns were raised about the security of Kenyans' health data.
Since returning to the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the US government, but Trump claimed its expenditure was "inefficient" and his government was pursuing direct bilateral deals to enhance openness and accountability.
Based on statements, Sixteen African countries have so far signed similar health pacts, constituting over $18.3bn in committed funds.
Details of the Declined Agreement
This assistance for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration might have yielded immense benefits for Zimbabwean communities, particularly the 1.2 million presently receiving antiretroviral therapy through US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"Our nation was requested to share its biological resources and data indefinitely, without any corresponding guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that shared data," he stated.
"Effectively, our country would provide the raw materials for medical research without any certainty that the resulting innovations would be accessible to our citizens should a future health crisis emerge."
Sovereignty and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were undermining systems previously set up through the global organization.
Mangwana cited its Pandemic Benefit-Sharing framework created to deal with potential global health emergencies.
"This system is intended to ensure that when a nation provides its data, the resulting advantages – including medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to create them."
These objections regarding the US deal "are not meant as opposition to America," he added.
"We welcome ongoing dialogue with our US partners on how subsequent co-operation could be structured in a way that respects the sovereignty and interests of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the official position, but recommended that talks need to persist considering much of the country's HIV programmes depended on external financing.
"If specific concerns exist, including those relating to data governance or agreement terms, these can often be resolved via detailed discussion and mutually agreed protections," it said.
The situation highlights the complex challenges between accepting much-needed international aid and protecting a country's data in an increasingly data-driven world.